Recent BioUtah News & Events

Senator Lee’s Deputy chief of staff Justin Anthony yesterday toured the new James LeVoy Sorenson Center for Medical Innovation (SCMI) at the University of Utah. The four-story, nearly 60,000-square-foot facility, led by Executive Director, Mark Paul, features advanced prototyping labs, a clinical bio-tissue surgery suite, and incubator spaces designed to foster, develop, and commercialize next-generation […]

Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultrasensitive superRCA Assay

Strategic investment in private AI infrastructure positions Owlet to compound value from its growing base of proprietary infant wellness data.

Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies

Behavioral Health Assessment Using Vocal Biomarkers

Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West

Report draws on Owlet’s massive infant sleep dataset, one of the world’s largest, to reveal how babies sleep – evaluating bedtimes, wake-ups, sleep stretches, and biometric trends

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease

SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of Economic Opportunity (GOEO), announced applications are now open for its second cohort program.

Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare companies with a premier platform to showcase innovations to experienced investors and industry leaders.

Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment

Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.

Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing

As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical

A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.

The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.

Merit Medical’s Fred Lampropoulos Honored by Nasdaq

Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million

Freyya Recognized at Transatlantic Angel Competition (TAAC8)

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.

In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells

Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas

Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History